135 related articles for article (PubMed ID: 22581915)
1. A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma.
Yoshino T; Kawai K; Miyazaki J; Kimura T; Ikeda A; Takaoka E; Suetomi T; Oikawa T; Kojima T; Iwasaki H; Shimano H; Nishiyama H
Jpn J Clin Oncol; 2012 Aug; 42(8):764-6. PubMed ID: 22581915
[TBL] [Abstract][Full Text] [Related]
2. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C
Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901
[TBL] [Abstract][Full Text] [Related]
3. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
4. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
5. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
6. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
[No Abstract] [Full Text] [Related]
7. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
9. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
10. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
Shinohara N; Takahashi M; Kamishima T; Ikushima H; Otsuka N; Ishizu A; Shimizu C; Kanayama H; Nonomura K
Br J Cancer; 2011 Jan; 104(2):241-7. PubMed ID: 21157447
[TBL] [Abstract][Full Text] [Related]
11. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
12. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
[TBL] [Abstract][Full Text] [Related]
15. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
16. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
17. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
18. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
19. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
20. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B; Porta C; Bono P; Powles T; Eisen T; Sternberg CN; Gschwend JE; De Giorgi U; Parikh O; Hawkins R; Sevin E; Négrier S; Khan S; Diaz J; Redhu S; Mehmud F; Cella D
J Clin Oncol; 2014 May; 32(14):1412-8. PubMed ID: 24687826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
